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Summary
 
Self-antigens expressed in extrathymic tissues such as the pancreas can be transported to draining
lymph nodes and presented in a class I–restricted manner by bone marrow-derived antigen-
presenting cells. Such cross-presentation of self-antigens leads to CD8
 
1
 
 T cell tolerance induc-
tion via deletion. In this report, we investigate the influence of CD4
 
1
 
 T cell help on this pro-
cess. Small numbers of autoreactive OVA-specific CD8
 
1
 
 T cells were unable to cause diabetes
when adoptively transferred into mice expressing ovalbumin in the pancreatic 
 
b
 
 cells. Coinjec-
tion of OVA-specific CD4
 
1
 
 helper T cells, however, led to diabetes in a large proportion of
mice (68%), suggesting that provision of help favored induction of autoimmunity. Analysis of
the fate of CD8
 
1
 
 T cells indicated that CD4
 
1
 
 T cell help impaired their deletion. These data
indicate that control of such help is critical for the maintenance of CD8
 
1
 
 T cell tolerance in-
duced by cross-presentation.
 
T
 
here is now considerable evidence that CD8
 
1
 
 T cell
responses can be induced in vivo by professional APCs
capable of MHC class I–restricted presentation of exoge-
nous antigens (1–3). This mechanism is known as cross-
presentation and was suggested to be instrumental in the
immune response to pathogens that avoid professional APCs
(2–4). However, if this pathway was only directed towards
induction of immunity, cross-presentation of self-antigens
to autoreactive CD8
 
1
 
 T cells would result in autoimmu-
nity. Recently, in studies using transgenic mice that express
a membrane-bound form of OVA under the control of the
rat insulin promoter (RIP-mOVA), we have shown that
this is not the case. RIP-mOVA mice express membrane-
bound OVA in pancreatic islets, kidney proximal tubular
cells, thymus and testis. In these mice, OVA was found to
enter the class I presentation pathway of a bone marrow–
derived cell population and then activate transgenic OVA-
specific CD8
 
1
 
 T cells (OT-I cells) (3) in LNs draining the
sites of antigen expression. Although this form of activation
initially led to proliferation of OT-I cells, it ultimately
caused their deletion (5). Thus, cross-presentation can re-
move autoreactive CD8
 
1
 
 T cells, and may tolerize the
CD8
 
1
 
 T cell compartment to self-antigens. These studies,
however, did not explain why cross-presentation of a self-
antigen induced CD8
 
1
 
 T cell tolerance, whereas foreign
antigens induced immunity (1–4, 6).
In numerous models, CD4
 
1
 
 T cell help has been shown
to be important for the induction or maintenance of im-
mune responses by CD8
 
1
 
 T cells (7–11), but such help is
not always essential (12–14). CD4
 
1
 
 T cell help has also been
shown to be important for avoiding CTL tolerance induc-
tion (15–17). In these reports, however, it was not known
whether CD8
 
1
 
 T cells were activated by cross-presentation
or by direct recognition of antigen. Thus, whether CD4
 
1
 
T cell help can affect tolerance induced by cross-presenta-
tion has not been addressed. Recently, we demonstrated that
cross-priming by foreign antigens requires CD4
 
1
 
 T cell help
for induction of CTL immunity (6). In this study, we have
investigated the influence of such help on the deletion of
CD8
 
1
 
 T cells induced by cross-presentation of self-anti-
gens.
 
Materials and Methods
 
Mice.
 
All mice were bred and maintained at the Walter and
Eliza Hall Institute for Medical Research. OT-II (18), OT-I
RAG-1 and RIP-mOVA transgenic mice (3) have been de-
scribed. Bone marrow chimeras were generated as described (5).
 
Adoptive Transfer and Flow Cytometry.
 
Preparation and 5,6-
carboxy-succinimidyl-fluoresceine-ester (CFSE)-labeling of OT-I
and OT-II cells, as well as analysis on a FACScan
 
Ò
 
 (Becton Dick-
inson and Co., Mountain View, CA) were carried out as de-
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scribed (3, 5, 19). The following mAbs were used for immu-
nostaining: PE conjugated anti-CD8 (YTS 169.4) and anti-CD4
(YTS 191.1) from Caltag Labs. (San Francisco, CA); anti-V
 
a
 
2
TCR (B20.1) and anti-V
 
b
 
5.1/2 TCR (MR9-4).
 
Immunohistology.
 
Frozen tissue sections were stained with
anti-CD8 supernatant (53.6.72 hybridoma), anti-CD4 ascites
(H129.19 hybridoma) or with anti-V
 
a
 
2 supernatant (B20.1), fol-
lowed by anti-rat Ig-horseradish peroxidase (Chemicon, Temec-
ula, CA) and DAB (Sigma) as described (20). Slides were coun-
terstained with hematoxylin.
 
Results
 
High Numbers of OT-I Cells Induce Diabetes in RIP-
mOVA Mice.
 
In previous studies, OT-I cells adoptively
transferred into RIP-mOVA mice were shown to be acti-
vated by cross-presentation of OVA in the draining LNs of
OVA-expressing tissues (3). When a relatively large num-
ber of OT-I cells (5 
 
3
 
 10
 
6
 
) was transferred, autoimmune
diabetes was observed within 5–8 d (5). To investigate the
dose response for induction of autoimmunity, various
numbers of OT-I cells were transferred into RIP-mOVA
mice (Table 1). 5–10 
 
3
 
 10
 
6
 
 OT-I cells caused 100% of mice
to develop diabetes. 50% of the recipients became diabetic
when 1 
 
3
 
 10
 
6
 
 OT-I cells were transferred, and 0.25 
 
3
 
 10
 
6
 
cells failed to cause disease in any of 26 recipients. Never-
theless, even with small numbers of OT-I cells transferred,
their activation and proliferation occurred in the draining
LNs (data not shown).
Histological examination revealed that on day 5 after
adoptive transfer of 5 
 
3
 
 10
 
6
 
 OT-I cells, the pancreatic islets
of RIP-mOVA recipients were densely infiltrated with
CD8
 
1
 
 T cells (Fig. 1 
 
A
 
) and with CD4
 
1
 
 T cells, B cells,
and MAC-1–positive cells, which were of host origin (data
not shown). Recipients of 1 
 
3
 
 10
 
6
 
 OT-I cells that did not
develop diabetes showed some CD8
 
1
 
 T cells within the is-
lets on day 8 (Fig. 1 
 
C
 
), whereas recipients of less OT-I
cells showed only sporadic islet infiltration (data not
shown).
 
Coinjection of OT-II Cells Can Induce Autoimmune Diabetes
in RIP-mOVA Recipients of a Low Number of OT-I Cells.
 
Both the CD4
 
1
 
 and CD8
 
1
 
 T cell compartments of RIP-
mOVA mice were tolerant to OVA as measured by the
ability to provide carrier-specific help (21), and to generate
 
Table 1.
 
Autoimmune Diabetes in RIP-mOVA Mice Depends on 
the Number of Adoptively Transferred OT-I Cells
 
No. of OT-I
cells transferred
No. mice diabetic/
total No. mice (%)
10 
 
3
 
 10
 
6
 
3/3 (100%)
5 
 
3
 
 10
 
6
 
18/18 (100%)
2 
 
3
 
 10
 
6
 
9/10 (90%)
1 
 
3
 
 10
 
6
 
4/8 (50%)
0.5 
 
3
 
 10
 
6
 
1/12 (8%)
0.25 
 
3
 
 10
 
6
 
0/26 (0%)
0.10 
 
3
 
 10
 
6
 
0/7 (0%)
Various numbers of V
 
a
 
2
 
1
 
 V
 
b
 
5
 
1 
 
CD8
 
1
 
 cells prepared from OT-I
RAG
 
2
 
/
 
2
 
 mice were injected i.v. into unirradiated RIP-mOVA mice
between 6 and 8 wk of age. These recipients were monitored daily for
glucosuria. Mice that did not develop diabetes were monitored for at
least 25 d and 5 recipients of 0.25 
 
3
 
 10
 
6
 
 OT-I cells for 210 d. These
data have been accumulated over six experiments.
Figure 1. Islet infiltration in
RIP-mOVA recipients of OT-I
and OT-II cells. The following
numbers of OT-I and OT-II
cells were adoptively transferred
into unirradiated RIP-mOVA
mice. (A) 5 3 106 OT-I cells;
(B) 0.25 3 106 OT-I cells 1 2 3
106 OT-II cells; (C) 1 3 106
OT-I cells; (D) 10 3 106 OT-II
cells. Sections of the pancreas
were stained 5 (A, B, and D) or 8 d
(C) after adoptive transfer for
CD8 (A–C) or CD4 (D). Ar-
rows in C indicate infiltrating
CD81 cells. 
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OVA-specific CTL (6), respectively (data not shown). This
tolerance was most likely due to aberrant expression of
mOVA in the thymus, as previously reported (3). Conse-
quently, neither CD4
 
1
 
 nor CD81 T cells specific for OVA
were present in these mice prior to adoptive transfer.
To determine whether CD41 T cell help could affect
the response of OT-I cells, such help was provided by
coinjection of CD41 T cells from OT-II transgenic mice
(OT-II cells), which produce H-2Ab–restricted T helper cells
specific for OVA. When RIP-mOVA mice were coin-
jected with 2 3 106 OT-II CD41 cells and a low number
of OT-I CD81 cells (0.25 3 106), approximately two-
thirds of the recipients developed diabetes (Table 2). 5 d after
adoptive transfer, islets were densely infiltrated by CD81
T cells (Fig. 1 B). It is important to note that OT-II cells
alone, even when injected at a higher dose (10 3 106 cells),
were unable to cause islet infiltration (Fig. 1 D) or autoim-
mune diabetes (Table 2). Thus, the availability of CD41
T cell help enhanced the response of OT-I cells, suggesting
that such help may direct a normally tolerogenic CD81 T cell
response (with low doses of OT-I cells) towards autoim-
munity, as measured by immunopathology.
CD41 T Cell Help Prolongs the Lifespan of CD81 T Cells
Specific for Cross-presented Autoantigens. We then investigated
whether OT-II cells achieved this effect by increasing the
initial expansion of OT-I cells, or by impairing their de-
letion. To examine the first possibility, CFSE-labeled OT-I
cells were adoptively transferred into RIP-mOVA mice in
the presence or absence of coinjected OT-II cells. This
technique enables monitoring of proliferation by detecting
cells with 2n-fold reduced fluorescence intensity, where n is
the number of cell cycles (5, 19). 2 d after adoptive transfer,
we compared the CFSE fluorescence profiles of OT-I cells
from the draining LNs of the kidney (Fig. 2) or pancreas
(data not shown). 2 3 106 OT-II cells did not cause an ob-
vious change in the proliferative peaks in these sites. No
changes were observed with smaller numbers of CFSE-
labeled OT-I cells (0.5 3 106), or at later time points (data
not shown). These results suggested that the rate of OT-I
cell cycling was not affected by OT-II cell help.
An alternative possibility was that CD41 T cell help in-
creased the survival of OT-I cells. To test this, it was neces-
sary to generate chimeric mice that would not become dia-
betic when given OT-I cells. This could be achieved by
back-crossing RIP-mOVA mice to the bm1 haplotype,
which expresses the Kbm1 molecule instead of Kb and can-
not present OVA to OT-I cells. By lethally irradiating and
reconstituting these mice with B6 bone marrow, chimeric
mice were generated that could present OVA on their
bone marrow–derived cells, but not on peripheral tissues.
These bone marrow chimeras were previously used to show
that cross-presentation of self-antigen can lead to the dele-
tion of autoreactive CD81 T cells (5). To determine
whether CD41 T cell help could affect CD81 T cell sur-
vival, these B6®RIP-mOVA.bm1 chimeric mice and
B6®littermate.bm1 controls were injected with 5 3 106
OT-I cells either alone or together with 2 3 106 OT-II
cells. After 6 wk, mice were sacrificed and the total number
of OT-I cells in the spleen and LNs was assessed (Fig. 3). In
9 of 10 transgenic recipients of OT-II cells, this number
clearly exceeded that in mice given OT-I cells alone, sug-
gesting that CD41 T cell help improved the survival of
CD81 T cells stimulated by cross-presentation. Islet infiltra-
tion or diabetes did not develop in B6®RIP-mOVA.bm1
chimeric mice coinjected with OT-I and OT-II cells (data
not shown) indicating that induction of diabetes was de-
pendent on class I–restricted antigen recognition on islet
b cells.
Figure 2. OT-II cells do not enhance proliferation of OT-I cells in the
draining LNs. 2 3 106 CFSE-labeled OT-I cells were adoptively trans-
ferred into littermate RIP-mOVA mice alone (A and B) or together with
2.5 3 106 OT-II cells (C and D). After 52 h, lymphocytes from the renal
(A and C) and inguinal (B and D) LNs were analyzed by flow cytometry.
Profiles were gated on CFSE1 CD81 cells. The numbers indicate the per-
centage of OT-I cells that had proliferated in vivo. These results are rep-
resentative of five experiments.
Table 2. Incidence of Diabetes after Cotransfer of OT-I and OT-II 
Cells
No. cells transferred
No. mice diabetic/
total No. mice (%) OT-I OT-II
5 3 106 2 18/18 (100%)
0.25 3 106 2 0/26 (0%)
0.25 3 106 2 3 106 15/22 (68%)
2 2 3 106 0/12 (0%)
2 10 3 106 0/3 (0%)
0.25 3 106 OT-I cells were transferred either alone or together with 2
3 106 OT-II cells into sex matched RIP-mOVA mice of 6–8 wk of
age. Coinjected recipients developed diabetes between day 6 and 10 af-
ter adoptive transfer and were sacrificed for histological verification of
diabetes after a further 5–10 d. Mice which did not become diabetic
were followed for 60–210 d. Shown are the results collected from 5
coinjection experiments with groups of 3–5 mice. The first two rows of
this table were included from Table 1 for comparison.2060 CD41 T Cell Help Can Convert CD81 T Cell Self–Tolerance into Autoimmunity
Discussion
In this study, we have used the transgenic RIP-mOVA
model to investigate the influence of CD41 T cell help on the
fate of autoreactive CD81 T cells activated by cross-presen-
tation of self-antigens. We have previously shown that naive
OT-I cells, when adoptively transferred into RIP-mOVA
mice, were activated by cross-presentation in LNs draining
OVA-expressing tissues (3). After an initial expansion
phase, this form of activation ultimately led to the deletion
of OT-I cells (5), and may thus represent a mechanism that
maintains CD81 T cell tolerance to self. This conclusion
highlighted the difference between cross-presentation of self
versus foreign antigens, the latter generally inducing immu-
nity (1–4, 6). Here, we demonstrate that OT-I cells acti-
vated by cross-presentation of self-antigens can induce islet
b cell destruction. This could occur even in the absence of
CD41 T cell help, but only with a relatively large dose of
OT-I cells (5 3 106). Transfer of such a high number of au-
toreactive CD81 T cells allowed the initial wave of ex-
pansion to generate sufficient CTL to destroy all pancreatic
b cells, before the CTL could be deleted. When the num-
ber of OT-I cells was lowered, they were deleted before
inducing diabetes. Thus, when precursor frequencies are low,
the dynamic process of proliferation versus deletion is bi-
ased towards the latter, particularly in the absence of CD41
T cell help. Introduction of such help, provided by coin-
jecting OT-II cells, allowed low doses of OT-I cells to
induce diabetes. This enhancing effect of OT-II cells was
not exerted by increasing the proliferative rate of OT-I cells.
Our results also argue against the interpretation that OT-I
cells stimulated OT-II cells to destroy pancreatic b cells,
because the induction of diabetes depended on MHC class
I–restricted antigen recognition in islet cells, and because
mouse islet b cells normally do not express MHC class II
molecules (22). The mechanism supported by our findings
is that CD41 T cell help enhanced the survival of activated
CD81 T cells, allowing them more time to exert effector
functions, possibly due to the induction of survival genes
like bcl-xL. Thus, the balance between proliferation and de-
letion of autoreactive CD81 T cells can be shifted towards
an immunogenic response if CD41 T cell help is available.
This interpretation does not exclude other factors influenc-
ing this balance, such as inflammatory signals supplied by
pathogens or material released from dying cells. In the
present model, however, OT-II cells were able to shift the
balance in favor of autoimmunity in the absence of any de-
tectable inflammatory signals.
Previous studies investigating the influence of CD41 T cell
help on CTL tolerance have used foreign antigens. For ex-
ample, responses to Qa1 and H-Y (16) were tolerogenic in
the absence of CD41 T cell help. Furthermore, survival of
H-Y–specific transgenic T cells, which normally proliferate
and then die in response to priming by male spleen cells,
was increased by providing a stimulus for CD41 T cells
(17). This was consistent with our current observations,
suggesting that CD41 T cell help is not necessary for the
initial proliferative response, but for the survival of subse-
quently produced CD81 T cells. Perhaps, this also explains
why CD81 T cell immunity to many viral infections (11,
12, 14), but not CD81 T cell memory (10, 11) can be in-
duced in the absence of CD41 T cell help.
The present study does not elucidate whether CD41 T
cell help was provided at the site of antigen-expression,
e.g., in the pancreatic islets, or in the draining LNs. How-
ever, we have recently reported that generation of OVA-
specific CTL by cross-priming, in another model, required
cognate CD41 T cell help (6). Thus, CD41 and CD81 T cells
had to recognize antigen on the same APC in order to gen-
erate CTL immunity. In the present model it is not known
whether cognate antigen recognition was required. If so,
OT-II cells might influence the inductive phase of the au-
toreactive response by activating the cross-presenting APC
such that it provided immunogenic rather than tolerogenic
signals to CD81 T cells. This may be mediated by signals
like CD40-L, which induces the upregulation of costimu-
latory molecules such as B7 (23, 24) and the synthesis of
IL-12 by the APC (25). Alternatively, CD41 T cells may
supply cytokines, such as IL-2, that enhance the expansion
and/or survival of CD81 T cells (17). Consistent with the
view that CD41 T cell help is required during priming,
CD81 T cell memory to H-Y persisted in the absence of
CD41 T cell help, provided such help was available during
the initial priming phase (26).
The ability of antigen expressed on non-lymphoid tissues
Figure 3. OT-II cells impair the deletion of OT-I cells activated by
cross-presentation. Bone marrow from B6 mice was grafted into irradi-
ated RIP-mOVA.bm1 mice and nontransgenic littermates. 12 wk later,
5 3 106 OT-I cells 6 2 3 106 OT-II cells were adoptively transferred,
and after 6 wk the number of Va21 Vb51 CD81 cells in the LNs and
spleen of the recipients was determined by flow cytometry. An average of
1.4% of CD81 cells were Va21 Vb5 1 in uninjected mice. The total
number of OT-I cells was derived using the formula: (%Va21 Vb51 cells
in the CD81 cells 2 1.4%) 3 (%CD81 T cells in live cells) 3 (number of
live cells). The figure shows the results of two experiments (s, e). The
numbers and bars indicate the average number of OT-I cells in mice from
both experiments. Injection of OT-II cells alone did not alter the propor-
tion of host CD42 Va21 Vb51 cells.2061 Kurts et al. Brief Definitive Report
to cross-prime naive CD81 T cells in the draining LNs might
provide a plausible mechanism whereby infected cells and
perhaps even malignant cells that lack the molecular ma-
chinery for direct immune induction, could prime CD81
T cells (1–4). This, however, raises the question of how could
CD81 T cells distinguish between viral antigens expressed
on virus-infected tissue cells, which they must kill, and self-
antigens on normal tissue cells, which they must leave in-
tact. As the availability of CD41 T cell help appears to be
responsible for dictating whether the CD81 T cell response
is immunogenic or tolerogenic, it is possible that the im-
mune system controls autoreactive CD81 T cells by limit-
ing the availability of CD41 T cell help (16). That is, in
contrast to the situation with pathogens, the CD41 T cell
repertoire might normally be tolerized to self-antigens. Thus,
CD41 T-cell help would not be available for self-reactive
CD81 T cell responses, resulting in the deletion of this pop-
ulation. In the present model, the CD41 T cell compart-
ment was tolerant to OVA because of thymic negative
selection. Future studies will address mechanisms of periph-
eral CD41 tolerance to self-antigens that are not expressed
in the thymus.
In conclusion, we have shown that, in the presence of
CD41 T cell help, CD81 T cell deletion induced by cross-
presentation of self-antigens is diminished, leading to auto-
immunity. Thus, by limiting such help, the immune system
can maintain peripheral CD81 T cell tolerance to self.
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